Cover Image
市場調查報告書

Integrin Alpha 4:開發中產品分析

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 364858
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
Integrin Alpha 4:開發中產品分析 Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H1 2016
出版日期: 2016年06月28日 內容資訊: 英文 80 Pages
簡介

本報告提供以Integrin Alpha 4為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

Integrin Alpha 4 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Antisense Therapeutics Limited
  • Atox Bio Ltd.
  • Biogen, Inc.
  • BioMAS Ltd.
  • 第一三共
  • EA Pharma Co Ltd
  • Protagonist Therapeutics Inc.
  • 武田藥品工業

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0147TDB

Summary

Global Markets Direct's, 'Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H1 2016', provides in depth analysis on Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted pipeline therapeutics.

The report provides comprehensive information on the Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)
  • The report reviews Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) Overview
  • Therapeutics Development
    • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Products under Development by Stage of Development
    • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Products under Development by Therapy Area
    • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Products under Development by Indication
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Products under Development by Companies
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Companies Involved in Therapeutics Development
    • Antisense Therapeutics Limited
    • Atox Bio Ltd.
    • Biogen, Inc.
    • BioMAS Ltd.
    • Daiichi Sankyo Company, Limited
    • EA Pharma Co Ltd
    • Protagonist Therapeutics Inc.
    • Takeda Pharmaceutical Company Limited
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Drug Profiles
    • AB-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AS-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATL-1102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • carotegrast - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • natalizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PTG-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit VLA-4 for Asthma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Integrin Alpha4 and Integrin Beta7 for Inflammatory Bowel Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vedolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Dormant Projects
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Discontinued Products
  • Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Featured News & Press Releases
    • Jun 01, 2016: Antisense provides update on ATL1102 clinical trials
    • May 31, 2016: Biogen Receives Positive CHMP Opinion for TYSABRI (Natalizumab) Use in Highly Active RRMS Patients with Inadequate Response to Prior MS Therapy
    • May 26, 2016: Elan Pharma International Withdraw an application for a change to the marketing authorisation for Tysabri (natalizumab)
    • May 24, 2016: Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis at 2016 Digestive Disease Week Annual Meeting
    • May 17, 2016: Protagonist Therapeutics to Present New Data on PTG-100 at Digestive Disease Week 2016
    • Apr 12, 2016: Biogen to Present Data on TYSABRI (Natalizumab) at 2016 AAN Annual Meeting
    • Mar 19, 2016: New Data Presented at European Crohn's and Colitis Organisation Scientific Meeting on Efficacy of Long-Term Vedolizumab Treatment
    • Feb 26, 2016: EMA confirms recommendations to minimise risk of brain infection PML with Tysabri
    • Feb 12, 2016: Updated recommendations to minimise the risk of the rare brain infection PML with Tysabri
    • Jan 15, 2016: Pharmacovigilance Risk Assessment Committee (PRAC) provides update on ongoing referral on Tysabri
    • Jan 08, 2016: Protagonist Therapeutics Initiates Phase 1 Study with Oral Peptide PTG-100
    • Dec 07, 2015: Atox Bio Enrolls First Patient in Phase 3 Study of Potential Treatment for Necrotizing Soft Tissue Infection (Flesh Eating Bacteria)
    • Oct 21, 2015: Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS
    • Oct 19, 2015: Takeda Presents Vedolizumab Data at the 2015 American College of Gastroenterology Annual Meeting and United European Gastroenterology Week
    • Oct 12, 2015: Antisense Therapeutics Provides ATL1102 Early Access Program Update
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Antisense Therapeutics Limited, H1 2016
  • Pipeline by Atox Bio Ltd., H1 2016
  • Pipeline by Biogen, Inc., H1 2016
  • Pipeline by BioMAS Ltd., H1 2016
  • Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Pipeline by EA Pharma Co Ltd, H1 2016
  • Pipeline by Protagonist Therapeutics Inc., H1 2016
  • Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Dormant Projects (Contd..2), H1 2016
  • Dormant Projects (Contd..3), H1 2016
  • Dormant Projects (Contd..4), H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top